Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Author:
Affiliation:
1. Teneobio, Inc., Menlo Park, CA, USA
2. Department of Laboratory Medicine, University of California, San Francisco, CA, USA
Funder
information to disclose
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
https://tandfonline.com/doi/pdf/10.1080/19420862.2019.1574521
Reference44 articles.
1. CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape
2. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
3. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody
4. Hybrid antibodies can target sites for attack by T cells
5. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Cited by 74 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09
2. Immune‐related adverse events of antibody‐based biological medicines in cancer therapy;Journal of Cellular and Molecular Medicine;2024-07
3. Development of a 10 g/L process for a difficult-to-express multispecific antibody format using a holistic process development approach;Journal of Biotechnology;2024-06
4. Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy;Acta Pharmaceutica Sinica B;2024-06
5. Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors;Biomedicine & Pharmacotherapy;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3